BHRT Study Shows 35.5% Lower Incidence of Breast Cancer in Women Treated with Subcutaneous Testosterone
As part of our ongoing dedication to sharing research and clinically proven outcomes in our industry, we're proud to announce the publication of a new groundbreaking study by BioTE founder Gary Donovitz, MD, FACOG, and Mandy Cotten, DNP, APRN, FNP-C in the peer-reviewed "European Journal of Breast Health".
This 9-year study found that women who took testosterone via hormone pellets as part of bioidentical hormone replacement therapy (BHRT) had a 35.5% lower incidence of invasive breast cancer compared to expected age-adjusted Surveillance Epidemiology and End Results (SEER) rates.
Key Study Takeaways:
- A retrospective study with 9 years of data (Jan. 2010-Oct. 2020)
- Included real-world data of 2,337 patients (women ages 29-87)
- Showed a 35.5% lower incidence of invasive breast cancer Second, and largest, long-term study showing such benefits
Read the full press release to learn more about this study and its potential impact.
Share The Study With Your Friends, Colleagues, & Patients
This study is a key addition to our knowledge of the potential long-term benefits of hormone therapy – as a Certified BioTE Provider, we want to help you spread the word! We've created a social media toolkit with images and text for Facebook and Instagram that you can use as-is or as inspiration for your own posts.
Click the link below to download your social media kit and start sharing today!
